---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000002"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:56:50.817478+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# AEON Biopharma issues corporate presentation with no new material facts

## Summary
- Presentation dated January 2026 made available on IR website (Item 7.01).
- Reiterates ABP-450 as biosimilar to BOTOX, aiming to be first complete therapeutic alternative.
- No financial or clinical data disclosed; no guidance or milestones provided.

## SEC filing metadata
- accession: 0001837607-26-000002
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/0001837607-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000002/aeon-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000002
- JSON: https://secwatch.observer/filing/0001837607-26-000002.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.